89 related articles for article (PubMed ID: 14519892)
1. Pilot study of oral rapamycin to prevent restenosis in patients undergoing coronary stent therapy: Argentina Single-Center Study (ORAR Trial).
Rodriguez AE; Alemparte MR; Vigo CF; Pereira CF; Llaurado C; Russo M; Virmani R; Ambrose JA
J Invasive Cardiol; 2003 Oct; 15(10):581-4. PubMed ID: 14519892
[TBL] [Abstract][Full Text] [Related]
2. Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial).
Rodríguez AE; Rodríguez Alemparte M; Vigo CF; Fernández Pereira C; Llauradó C; Vetcher D; Pocovi A; Ambrose J
Heart; 2005 Nov; 91(11):1433-7. PubMed ID: 15774608
[TBL] [Abstract][Full Text] [Related]
3. Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study.
Rodriguez AE; Granada JF; Rodriguez-Alemparte M; Vigo CF; Delgado J; Fernandez-Pereira C; Pocovi A; Rodriguez-Granillo AM; Schulz D; Raizner AE; Palacios I; O'Neill W; Kaluza GL; Stone G;
J Am Coll Cardiol; 2006 Apr; 47(8):1522-9. PubMed ID: 16630986
[TBL] [Abstract][Full Text] [Related]
4. Oral rapamycin to prevent human coronary stent restenosis: a pilot study.
Guarda E; Marchant E; Fajuri A; Martínez A; Morán S; Mendez M; Uriarte P; Valenzuela E; Lazen R
Am Heart J; 2004 Aug; 148(2):e9. PubMed ID: 15309012
[TBL] [Abstract][Full Text] [Related]
5. A comparison of clinical and angiographic outcomes after Excel bioabsorbable polymer versus Firebird durable polymer rapamycin-eluting stent for the treatment of coronary artery disease in a "real world" setting: six-month follow-up results.
Liu HB; Xu B; Qiao SB; Yang YJ; Ma WH; Qin XW; Yao M; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Li JJ; Chen JL; Gao RL
Chin Med J (Engl); 2007 Apr; 120(7):574-7. PubMed ID: 17442205
[TBL] [Abstract][Full Text] [Related]
6. Pilot trial of oral rapamycin for recalcitrant restenosis.
Brara PS; Moussavian M; Grise MA; Reilly JP; Fernandez M; Schatz RA; Teirstein PS
Circulation; 2003 Apr; 107(13):1722-4. PubMed ID: 12665483
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of the 2.25-mm sirolimus-eluting Bx Velocity stent in the treatment of patients with de novo native coronary artery lesions: the SIRIUS 2.25 trial.
Moses JW; Nikolsky E; Mehran R; Cambier PA; Bachinsky WB; Leya F; Kuntz RE; Popma JJ; Schleckser P; Wang H; Cohen SA; Leon MB;
Am J Cardiol; 2006 Dec; 98(11):1455-60. PubMed ID: 17126649
[TBL] [Abstract][Full Text] [Related]
8. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial.
Sabaté M; Jiménez-Quevedo P; Angiolillo DJ; Gómez-Hospital JA; Alfonso F; Hernández-Antolín R; Goicolea J; Bañuelos C; Escaned J; Moreno R; Fernández C; Fernández-Avilés F; Macaya C;
Circulation; 2005 Oct; 112(14):2175-83. PubMed ID: 16203930
[TBL] [Abstract][Full Text] [Related]
9. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial.
Vermeersch P; Agostoni P; Verheye S; Van den Heuvel P; Convens C; Bruining N; Van den Branden F; Van Langenhove G
J Am Coll Cardiol; 2006 Dec; 48(12):2423-31. PubMed ID: 17174178
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus versus bare metal stent implantation in patients with total coronary occlusions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease (SCANDSTENT) trial.
Kelbaek H; Helqvist S; Thuesen L; Kløvgaard L; Jørgensen E; Saunamäki K; Krusell LR; Bøtker HE; Engstrøm T; Jensen GV;
Am Heart J; 2006 Nov; 152(5):882-6. PubMed ID: 17070149
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin-eluting stents for the treatment of bifurcated coronary lesions: a randomized comparison of a simple versus complex strategy.
Pan M; de Lezo JS; Medina A; Romero M; Segura J; Pavlovic D; Delgado A; Ojeda S; Melián F; Herrador J; Ureña I; Burgos L
Am Heart J; 2004 Nov; 148(5):857-64. PubMed ID: 15523318
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of oral sirolimus to inhibit in-stent intimal hyperplasia.
Brito FS; Rosa WC; Arruda JA; Tedesco H; Pestana JO; Lima VC
Catheter Cardiovasc Interv; 2005 Apr; 64(4):413-8. PubMed ID: 15789385
[TBL] [Abstract][Full Text] [Related]
14. Outcome of percutaneous hybrid coronary revascularization: bare metal stents jeopardize the benefit of sirolimus-eluting stents in the real world.
Fineschi M; Gori T; Pierli C; Casini S; Sinicropi G; Buti A; Del Pasqua A; Bravi A
Can J Cardiol; 2005 Dec; 21(14):1281-5. PubMed ID: 16341297
[TBL] [Abstract][Full Text] [Related]
15. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
[TBL] [Abstract][Full Text] [Related]
16. Firebird and cypher sirolimus-eluting stents and bare metal stents in treatment of very long coronary lesions.
Fan L; Chen LL; Lin CG; Peng YF; Zheng XC; Luo YK; Zhang FL; Chen JH; Yan XP; Huang ZR
Chin Med J (Engl); 2008 Aug; 121(16):1518-23. PubMed ID: 18982862
[TBL] [Abstract][Full Text] [Related]
17. Early outcome of treatment of ostial de novo left anterior descending coronary artery lesions with drug-eluting stents.
Tsagalou E; Stankovic G; Iakovou I; Melzi G; Cosgrave J; Ge L; Michev I; Chieffo A; Airoldi F; Carlino M; Montorfano M; Colombo A
Am J Cardiol; 2006 Jan; 97(2):187-91. PubMed ID: 16442360
[TBL] [Abstract][Full Text] [Related]
18. Clinical and angiographic outcome after sirolimus-eluting stent implantation in aorto-ostial lesions.
Iakovou I; Ge L; Michev I; Sangiorgi GM; Montorfano M; Airoldi F; Chieffo A; Stankovic G; Vitrella G; Carlino M; Corvaja N; Briguori C; Colombo A
J Am Coll Cardiol; 2004 Sep; 44(5):967-71. PubMed ID: 15337205
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of sirolimus-eluting stents in diabetics with complex coronary lesions].
Berenguer A; Mainar V; Bordes P; Valencia J; Gómez S
Rev Esp Cardiol; 2006 Feb; 59(2):117-24. PubMed ID: 16540032
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of lesions with a high risk of stenosis. Comparative study in 300 patients of rapamycin- and Paclitaxel-eluting polymer-based stents, and bare metal stents].
de la Torre Hernández JM; Sainz Laso F; Ruisánchez C; Zueco J; Figueroa A; Colman T
Rev Esp Cardiol; 2005 Mar; 58(3):262-9. PubMed ID: 15766448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
